ANDA 65217, held by Zydus Pharms USA. Clindamycin Hydrochloride.
As of Nov 16, 2026, ANDA 65217 (Clindamycin Hydrochloride), held by Zydus Pharms USA, was first approved by FDA on Jan 31, 2005, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 31, 2005 | Original application | Approved | None posted |
| Clindamycin HydrochlorideEQ 75MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Clindamycin HydrochlorideEQ 150MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Clindamycin HydrochlorideEQ 300MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Aug 19, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 27, 2011 | Supplement 2Labeling | Approved | None posted |
| Jan 31, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters